Potential risk of Pb to children's health from consumption of cow’s milk in areas irrigated with river water contaminated by mining activity

The contamination of food by heavy metals in areas irrigated with contaminated water is of great concern due to the potential risk to human health. To assess the potential risk of Pb to children's health from consumption of cow's milk in an area of the Mantaro Valley during 2018. Fifty-one children exposed to Pb and eight samples of raw cow's milk were selected. Pb concentrations were analyzed with the atomic absorption spectrometer. The mean Pb content in milk was 0.236 ± 0.057 mg.kg-1, which exceeded the limits allowed by the Codex Alimentarius. The estimated daily intake of lead was 5.9 x 10-3 mg.kg-1day-1; the estimated risk index (HQ) was below one, which represents a low risk for children. The cancer risk was below 1.0 x 10-4. It is therefore concluded that there is no significant risk to children's health from consumption of cow's milk

Knowledge of COVID-19 in the economically active population of Peru: validation study (KNOW-PER-COV)

"Introducción: El COVID-19 sigue siendo un problema sanitario a nivel mundial, pues es un virus que continúa evolucionando y la vacunación sigue presentando obstáculos. Es menester evaluar los conocimientos sobre COVID-19 de la población laboral, pues estos permiten respaldar una toma de decisiones en favor de la prevención. Objetivo: Validar una escala que mida conocimientos sobre COVID-19 que tiene la población laboral del Perú. Material y Métodos: Se confeccionó una escala de 10 preguntas, se las sometió a un juicio de expertos, se evaluó en un piloto y se hizo una encuesta a 663 trabajadores. Resultados: La V de Aiken fue mayor de 0,7 en todos los ítems. Se obtuvo un total de 9 ítems. Se evidenció que el ítem 3 fue el más difícil (ID = 63%). El alfa de Cronbach fue de 0,701 (0.65-0.74). Conclusiones: Se validó un instrumento, que puede medir efectivamente los conocimientos sobre COVID-19 de los trabajadores.

Knowledge of COVID-19 in the economically active population of Peru: validation study (KNOW-PER-COV)

"Introducción: El COVID-19 sigue siendo un problema sanitario a nivel mundial, pues es un virus que continúa evolucionando y la vacunación sigue presentando obstáculos. Es menester evaluar los conocimientos sobre COVID-19 de la población laboral, pues estos permiten respaldar una toma de decisiones en favor de la prevención. Objetivo: Validar una escala que mida conocimientos sobre COVID-19 que tiene la población laboral del Perú. Material y Métodos: Se confeccionó una escala de 10 preguntas, se las sometió a un juicio de expertos, se evaluó en un piloto y se hizo una encuesta a 663 trabajadores. Resultados: La V de Aiken fue mayor de 0,7 en todos los ítems. Se obtuvo un total de 9 ítems. Se evidenció que el ítem 3 fue el más difícil (ID = 63%). El alfa de Cronbach fue de 0,701 (0.65-0.74). Conclusiones: Se validó un instrumento, que puede medir efectivamente los conocimientos sobre COVID-19 de los trabajadores.

Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia

The treatment of chronic lymphocytic leukemia (CLL) patients with venetoclax-based regimens has demonstrated efficacy and a safety profile, but the emergence of resistant cells and disease progression is a current complication. Therapeutic target of sphingosine kinases (SPHK) 1 and 2 has opened new opportunities in the treatment combinations of cancer patients. We previously reported that the dual SPHK1/2 inhibitor, SKI-II enhanced the in vitro cell death triggered by fludarabine, bendamustine or ibrutinib and reduced the activation and proliferation of chronic lymphocytic leukemia (CLL) cells. Since we previously showed that autologous activated T cells from CLL patients favor the activation of CLL cells and the generation of venetoclax resistance due to the upregulation of BCL-XL and MCL-1, we here aim to determine whether SPHK inhibitors affect this process. To this aim we employed the dual SPHK1/2 inhibitor SKI-II and opaganib, a SPHK2 inhibitor that is being studied in clinical trials. We found that SPHK inhibitors reduce the activation of CLL cells and the generation of venetoclax resistance induced by activated T cells mainly due to a reduced upregulation of BCL-XL. We also found that SPHK2 expression was enhanced in CLL cells by activated T cells of the same patient and the presence of venetoclax selects resistant cells with high levels of SPHK2. Of note, SPHK inhibitors were able to re-sensitize already resistant CLL cells to a second venetoclax treatment. Our results highlight the therapeutic potential of SPHK inhibitors in combination with venetoclax as a promising treatment option for the patients

KNOWLEDGE OF COVID-19 IN THE ECONOMICALLY ACTIVE POPULATION OF PERU:VALIDATION STUDY (KNOW-PER-COV)

Introduction: COVID-19 continues to be a global health problem, as it is a virus that continues to evolve and vaccination continues to present obstacles. It is necessary to evaluate the knowledge about COVID-19 of the working population, since these allow supporting decision-making in favor of prevention. Objective:Validate a scale that measures knowledge about COVID-19 that the working population of Peru has. Material and Methods: A scale of 10 questions was made, submitted to expert judgment, evaluated in a pilot, and a survey of 663 workers was carried out. Results: Aiken’s V was greater than 0.7 in all items. A total of 9 items were obtained. Item 3 was found to be the most difficult (ID = 63%). Cronbach’s alpha was 0.701 (0.65-0.74). Conclusions: An instrument was validated, which can effectively measure workers’ knowledge about COVID-19.Revisión por pare

DataSheet_1_Venetoclax resistance induced by activated T cells can be counteracted by sphingosine kinase inhibitors in chronic lymphocytic leukemia.pdf

The treatment of chronic lymphocytic leukemia (CLL) patients with venetoclax-based regimens has demonstrated efficacy and a safety profile, but the emergence of resistant cells and disease progression is a current complication. Therapeutic target of sphingosine kinases (SPHK) 1 and 2 has opened new opportunities in the treatment combinations of cancer patients. We previously reported that the dual SPHK1/2 inhibitor, SKI-II enhanced the in vitro cell death triggered by fludarabine, bendamustine or ibrutinib and reduced the activation and proliferation of chronic lymphocytic leukemia (CLL) cells. Since we previously showed that autologous activated T cells from CLL patients favor the activation of CLL cells and the generation of venetoclax resistance due to the upregulation of BCL-XL and MCL-1, we here aim to determine whether SPHK inhibitors affect this process. To this aim we employed the dual SPHK1/2 inhibitor SKI-II and opaganib, a SPHK2 inhibitor that is being studied in clinical trials. We found that SPHK inhibitors reduce the activation of CLL cells and the generation of venetoclax resistance induced by activated T cells mainly due to a reduced upregulation of BCL-XL. We also found that SPHK2 expression was enhanced in CLL cells by activated T cells of the same patient and the presence of venetoclax selects resistant cells with high levels of SPHK2. Of note, SPHK inhibitors were able to re-sensitize already resistant CLL cells to a second venetoclax treatment. Our results highlight the therapeutic potential of SPHK inhibitors in combination with venetoclax as a promising treatment option for the patients.</p